ライフサイエンスコーパス: fibromyalgia

1 low back pain, systemic lupus erythematosus, fibromyalgia).

2 onic low back pain, knee osteoarthritis, and fibromyalgia).

3 ffers a therapeutic benefit in patients with fibromyalgia.

4 hysical and mental function in patients with fibromyalgia.

5 ry, and generalized pain conditions, such as fibromyalgia.

6 e inhibitors (duloxetine and milnacipran) in fibromyalgia.

7 cy and safety of gabapentin in patients with fibromyalgia.

8 and safety in treating pain associated with fibromyalgia.

9 tion on depressive symptoms in patients with fibromyalgia.

10 ated depressive symptoms among patients with fibromyalgia.

11 ible for the chronic diffuse pain typical of fibromyalgia.

12 t of pain and other symptoms associated with fibromyalgia.

13 t of any treatment plan for the patient with fibromyalgia.

14 would result in pain relief in patients with fibromyalgia.

15 f ailments from carbon monoxide poisoning to fibromyalgia.

16 r than sham acupuncture at relieving pain in fibromyalgia.

17 the group that received acupuncture to treat fibromyalgia.

18 sed by functional MRI among 29 subjects with fibromyalgia.

19 itamin D deficiency is often misdiagnosed as fibromyalgia.

20 ith rheumatoid arthritis, osteoarthritis, or fibromyalgia.

21 here are distinct subgroups of patients with fibromyalgia.

22 ribute to the development of the syndrome of fibromyalgia.

23 r other scales were highest in patients with fibromyalgia.

24 syndrome, the irritable bowel syndrome, and fibromyalgia.

25 cial than either drug alone in patients with fibromyalgia.

26 one breast implant recipients who often have fibromyalgia.

27 c fatigue syndrome is much less than that of fibromyalgia.

28 ases such as cancer, multiple sclerosis, and fibromyalgia.

29 Food and Drug Administration (FDA) to treat fibromyalgia.

30 's connectivity was significantly reduced in fibromyalgia.

31 a clear understanding of the pathogenesis of fibromyalgia.

32 low back pain to a high of 68% (n = 23) for fibromyalgia.

33 gional pain syndrome, sickle cell anemia, or fibromyalgia.

34 irst stimulated at 0.25Hz was more common in fibromyalgia.

35 ain and tenderness suffered by patients with fibromyalgia.

36 identify potential causal risk variants for fibromyalgia.

37 ly studied sample of patients diagnosed with fibromyalgia.

38 ns, and muscle twitches are common traits in fibromyalgia.

39 age scan to identify susceptibility loci for fibromyalgia.

40 study suggests a strong genetic component of fibromyalgia.

41 tensity in patients with neuropathic pain or fibromyalgia?

42 was found in 24.2% of silent nociceptors in fibromyalgia, 22.7% in small-fiber neuropathy, and 3.7%

43 LBP (3.9 kg) (P = 0.03) or the patients with fibromyalgia (3.5 kg) (P = 0.006).

44 was detected in 31% of silent nociceptors in fibromyalgia, 34% in small-fiber neuropathy, and 2.2% in

45 e of 2.1 million for 1995), 5.0 million have fibromyalgia, 4-10 million have carpal tunnel syndrome,

46 162 with rheumatoid arthritis (RA), 114 with fibromyalgia, 63 with osteoarthritis, 34 with systemic l

47 y bowel disease, hepatic encephalopathy, and fibromyalgia and burn injury.

48 The common co-existence of fibromyalgia and chronic abdominal pain could be due to

49 ated hypotension has been documented in both fibromyalgia and chronic fatigue syndrome.

50 tor-1 axis have been also documented in both fibromyalgia and chronic fatigue syndrome.

51 s of 30 female patients meeting criteria for fibromyalgia and compared with recordings from 17 female

52 al activity that applies to individuals with fibromyalgia and fits a counseling model of health behav

53 ith rheumatoid arthritis, osteoarthritis, or fibromyalgia and Internet and e-mail access (n = 855) we

54 lead to frequent health care use; for some, fibromyalgia and its symptoms can be debilitating.

55 Tai chi may be a useful treatment for fibromyalgia and merits long-term study in larger study

56 Fibromyalgia and other "centralized" pain states are muc

57 occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used

58 was unrelated to treatment (exacerbation of fibromyalgia and rectal bleeding).

59 ded new insights into the pathophysiology of fibromyalgia and related chronic pain disorders.

60 tically exacerbates pain in diseases such as fibromyalgia and rheumatoid arthritis, but the underlyin

61 and functional benefits for individuals with fibromyalgia and should be included in treatment plans.

62 tions in other rheumatic conditions, such as fibromyalgia and systemic sclerosis.

63 etween chronic or widespread pain (including fibromyalgia) and mortality were included.

64 sive symptoms are common among patients with fibromyalgia, and behavioral intervention has been recom

65 is/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome.

66 n, arthritis, persistent post-surgical pain, fibromyalgia, and neuropathic pain disorders, is highly

67 s with osteoarthritis, rheumatoid arthritis, fibromyalgia, and other musculoskeletal conditions.

68 of the RIM model to study sleep disorders in fibromyalgia, and provide new insights into the research

69 e, neuropathy, headache or tension headache, fibromyalgia, and psychogenic pain) and subsequent suici

70 001, compared to quintile 1/least deprived), fibromyalgia (aOR 1.81, 95% CI 1.49-2.19, p < 0.001), su

71 ciatica in adults less than 21 years of age, fibromyalgia, apophyseal and sacroiliac joint pain, and

72 In a subset of patients with fibromyalgia, approximately 50% of whom required narcoti

73 strated that chronic fatigue and symptoms of fibromyalgia are distributed as continuous variables in

74 While the basics of the treatment of fibromyalgia are included, the intent is to provide cont

75 n College of Rheumatology (ACR) criteria for fibromyalgia are the de facto criteria used for research

76 l activity and exercise for individuals with fibromyalgia are to improve or maintain general fitness,

77 n College of Rheumatology (ACR) criteria for fibromyalgia are used to identify individuals with both

78 sis and therapy is patients with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and

79 widespread pain is several times higher than fibromyalgia as defined by the 1990 American College of

80 A wide spectrum of fibromyalgia-associated symptomatology and syndromes con

81 s occurring during the study were related to fibromyalgia-associated symptoms.

82 dication used off-label for the treatment of fibromyalgia, but pregabalin, duloxetine, and milnacipra

83 pelling evidence of a familial clustering of fibromyalgia cases in female sufferers; whether this clu

84 s similar to systemic pain syndromes such as fibromyalgia, chronic fatigue and irritable bowel syndro

85 agnosis of the patients with sicca symptoms, fibromyalgia, chronic fatigue, vague cognitive defects,

86 chronic musculoskeletal conditions, such as fibromyalgia, chronic low back pain and myofascial pain.

87 Patients with fibromyalgia commonly have symptoms of abdominal pain, s

88 In treating fibromyalgia, compared with placebo, pregabalin alone is

89 Basic research in fibromyalgia continues to pinpoint abnormal sensory proc

90 ducation and stretching for the treatment of fibromyalgia (defined by American College of Rheumatolog

91 A proportion of people with fibromyalgia demonstrate small fibre pathology (SFP).

92 nt among deployed than nondeployed veterans: fibromyalgia (deployed, 2.0%; nondeployed, 1.2%; odds ra

93 Because there is no gold standard for fibromyalgia diagnosis and because fibromyalgia is often

94 able to provide physician verification of a fibromyalgia diagnosis.

95 ng the 2010 American College of Rheumatology Fibromyalgia diagnostic criteria undergoing high-dose TE

96 among patients who received acupuncture for fibromyalgia did not differ from that in the pooled sham

97 s, rheumatoid arthritis, osteoarthritis, and fibromyalgia differed significantly in their pain:ADL ra

98 article highlights the clinical features of fibromyalgia, discusses diagnostic criteria and their ev

99 heumatic disorder and pain syndromes such as fibromyalgia do not respond to traditional analgesic med

100 Fibromyalgia does not have a distinct cause or pathology

101 wel syndrome', 'Fibromyalgia', 'Dopamine and fibromyalgia', 'Dopamine and chronic fatigue syndrome' a

102 igue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and fibromyalgia', 'Dopamine an

103 tients with chronic pain, best classified as fibromyalgia, either primary or in association with othe

104 Accruing evidence shows that patients with fibromyalgia experience pain differently from the genera

105 al levels of pressure, patients with CLBP or fibromyalgia experienced significantly more pain and sho

106 e genotyped members of 116 families from the Fibromyalgia Family Study and performed a model-free gen

107 igation of these multicase families from the Fibromyalgia Family Study is warranted to identify poten

108 ven individuals meeting the ACR criteria for fibromyalgia finished the same battery of self-report an

109 Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are

110 outcomes were compared between patients with fibromyalgia (FM) and controls.

111 ive-behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disab

112 Fibromyalgia (FM) is a chronic widespread pain condition

113 Fibromyalgia (FM) is considered to be the prototypical c

114 evelopment of novel treatment strategies for fibromyalgia (FM) is the lack of an objective marker tha

115 A subset of fibromyalgia (FM) patients have a dysfunctional hypothal

116 Diagnosis and treatment of fibromyalgia (FM) remains a challenge owing to the lack

117 People with fibromyalgia (FM) report a number of physical, cognitive

118 Fibromyalgia (FM) represents a complex disorder that is

119 In evaluating the effectiveness of fibromyalgia (FM) therapies, it is important to assess t

120 t data derived from a study of patients with fibromyalgia (FM) to examine variability of pain over ti

121 The sensitivity for fibromyalgia (FM) was 0.48 (95% CI 0.28-0.68).

122 Fibromyalgia (FM), a common chronic pain condition chara

123 owing marked comorbidity with depression and fibromyalgia (FM), both of which are associated with dys

124 siology of functional pain syndromes such as fibromyalgia (FM).

125 er (MDD) on pain processing in patients with fibromyalgia (FM).

126 s (GWI), Chronic Fatigue Syndrome (CFS), and fibromyalgia (FM).

127 physiology of chronic pain syndromes such as fibromyalgia (FM).

128 nt review is intended to give an overview of fibromyalgia for the anesthesiologist.

129 and specificity of at least 80% in screening fibromyalgia from controls.

130 imia nervosa, cataplexy, dysthymic disorder, fibromyalgia, generalized anxiety disorder, irritable bo

131 table recordings of 186 C nociceptors in the fibromyalgia group, 114 from small-fiber neuropathy pati

132 d not differ from healthy controls in either fibromyalgia group.

133 hyperalgesia in this group as well as in the fibromyalgia group; the pressure required to produce sli

134 pain-related cortical areas in the CLBP and fibromyalgia groups (in the contralateral primary and se

135 Familial aggregation of fibromyalgia has been increasingly recognized.

136 acy of these interventions for patients with fibromyalgia has not been established.

137 Fibromyalgia has received the most attention albeit most

138 ms (such as the irritable bowel syndrome and fibromyalgia) have been shown to have significantly high

139 outcome measures were the total score on the Fibromyalgia Impact Questionnaire (FIQ) and FIQ VAS scor

140 The primary end point was a change in the Fibromyalgia Impact Questionnaire (FIQ) score (ranging f

141 iaries) on a visual analog scale (PVAS), the Fibromyalgia Impact Questionnaire (FIQ) score, and the P

142 Co-primary outcome measures were the Fibromyalgia Impact Questionnaire (FIQ) total score (sco

143 omes were the weekly mean pain score and the Fibromyalgia Impact Questionnaire (FIQ) total score at w

144 ore changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessme

145 Clinical outcomes, included the fibromyalgia impact questionnaire (FIQ), pain catastroph

146 measures included a tender point score, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depres

147 Secondary outcome measures were the Fibromyalgia Impact Questionnaire (FIQ), the Multidimens

148 Short Form 36 Health Survey (SF-36) and the Fibromyalgia Impact Questionnaire (FIQ).

149 (6-minute walk test), and functional status (Fibromyalgia Impact Questionnaire [FIQ]) before and afte

150 oms of fibromyalgia were evaluated using the Fibromyalgia Impact Questionnaire and the Short Form 36

151 ctively) with FM pain severity measured with fibromyalgia impact questionnaire revised version (FIQR)

152 severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score (all P < 0

153 the BPI average pain interference score, the Fibromyalgia Impact Questionnaire total score, the Clini

154 the Pittsburgh Sleep Quality Index, and the Fibromyalgia Impact Questionnaire.

155 ng the 206 patients, the clinician diagnosed fibromyalgia in 49.0%, while 29.1% satisfied ACR criteri

156 new tool to screen and detect patients with fibromyalgia in a fast, low-cost, non-destructive and mi

157 lf-report questionnaire for the diagnosis of fibromyalgia in lieu of the previously required tender p

158 atologists, and rheumatologists may diagnose fibromyalgia in patients who do not satisfy the ACR crit

159 ent for many of the symptoms associated with fibromyalgia in subjects with or without major depressiv

160 nerve fibers of the cornea of patients with fibromyalgia in terms of density, length and branching a

161 The prevalence of fibromyalgia in the general population was found to be 2

162 e most important pathophysiologic studies in fibromyalgia included evidence of altered blood flow to

163 ength was used to stratify participants with fibromyalgia into with SFP [SFP+] and without SFP [SFP-]

164 Fibromyalgia is a common chronic pain condition for whic

165 Fibromyalgia is a common chronic pain disorder character

166 Primary fibromyalgia is a common yet poorly understood syndrome

167 Recent evidence suggests that fibromyalgia is a disorder characterized by dysfunctiona

168 Fibromyalgia is a rheumatologic condition characterized

169 Fibromyalgia is characterized by chronic, widespread mus

170 Effective treatment for fibromyalgia is now possible.

171 ndard for fibromyalgia diagnosis and because fibromyalgia is often viewed as a trait diagnosis, all m

172 ic studies continue to provide evidence that fibromyalgia is part of a spectrum of chronic widespread

173 Fibromyalgia is present in as much as 2% to 8% of the po

174 The pathogenesis of fibromyalgia is still unknown.

175 Fibromyalgia, low LDL levels, high vitamin B(1) levels a

176 Fibromyalgia may be considered as a discrete diagnosis o

177 hematosus, amyotrophic lateral sclerosis, or fibromyalgia might be related to Gulf War service.

178 d anxiety (p < 0.05), and somatic syndromes; fibromyalgia, migraine and sleep disorders (p < 0.001) w

179 n overlap with nonpelvic pain disorders (eg, fibromyalgia, migraines) and nonpain comorbidities (eg,

180 we propose a method to detect patients with fibromyalgia (n = 252, 126 controls and 126 patients wit

181 n = 11, n = 19), arthralgia (n = 24, n = 7), fibromyalgia (n = 4, n = 11), and multiple symptoms with

182 LBP (n = 11), patients with widespread pain (fibromyalgia; n = 16), and healthy control subjects (n =

183 algia taking opioids (N = 17), patients with fibromyalgia not taking opioids (N = 17), and healthy co

184 tal cortex differed, such that patients with fibromyalgia not taking opioids demonstrated significant

185 The impact of fibromyalgia on anesthesia care is not known.

186 ority status, higher education, diagnosis of fibromyalgia or osteoarthritis, and poorer health.

187 een sexual abuse and a lifetime diagnosis of fibromyalgia (OR, 1.61; 95% CI, 0.85-3.07, I(2) = 0%; 4

188 ved between rape and a lifetime diagnosis of fibromyalgia (OR, 3.35; 95% CI, 1.51-7.46), chronic pelv

189 gram that was specifically designed to treat fibromyalgia, or 1 of 3 sham acupuncture treatments: acu

190 ic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

191 re enrolled in a 7-year prospective study of fibromyalgia outcome.

192 n central pain states) were shown to benefit fibromyalgia pain in an experimental setting.

193 Moderate-to-severe fibromyalgia pain significantly impairs HRQOL, and effec

194 nd study of patients with moderate-to-severe fibromyalgia pain.

195 rocessing as being integral to understanding fibromyalgia pain.

196 specific and clinically beneficial impact on fibromyalgia pain.

197 Thirty-one women with fibromyalgia participated in the randomized, double-blin

198 been shown to indicate pain sensitization in fibromyalgia patients and differentiate these patients f

199 Fibromyalgia patients averaged almost 10 outpatient medi

200 edures were used to distinguish subgroups of fibromyalgia patients based on these domains.

201 The mechanosensitive nociceptors in the fibromyalgia patients behaved normally, but the silent n

202 ally, but the silent nociceptors in 76.6% of fibromyalgia patients exhibited abnormalities.

203 Five hundred thirty-eight fibromyalgia patients from 6 rheumatology centers were e

204 Cognitive dysfunction in fibromyalgia patients has been reported, especially when

205 show for the first time that the majority of fibromyalgia patients have abnormal C nociceptors.

206 Fibromyalgia patients have high lifetime and current rat

207 Research continues to demonstrate that fibromyalgia patients have neurophysiologic abnormalitie

208 a and/or windup), yielded four phenotypes of fibromyalgia patients in a subgroup analysis: one group

209 ge yearly cost for service utilization among fibromyalgia patients is $2,274.

210 fore, it seems useful to identify subsets of fibromyalgia patients on the basis of which of these fac

211 use of additional non-opioid medications by fibromyalgia patients taking opioids, these preliminary

212 There appears to be a group of fibromyalgia patients who exhibit extreme tenderness but

213 The distinction between fibromyalgia patients with low titer antinuclear antibod

214 ing of conduction velocity is more common in fibromyalgia patients, and may constitute a distinguishi

215 e comorbid mood disorders are more common in fibromyalgia patients, studies have shown that fibromyal

216 del mimics the sleep disorders that occur in fibromyalgia patients.

217 ivity is associated with spontaneous pain in fibromyalgia patients.

218 nal cord lesions, but also disorders such as fibromyalgia, phantom limb pain and tension-type headach

219 In conclusion, half of the tested fibromyalgia population demonstrates signs of small fibe

220 ender point examination, survey criteria for fibromyalgia (Regional Pain Scale score > or =8 and fati

221 th study period, patients used a mean of 2.7 fibromyalgia-related drugs.

222 Participants with fibromyalgia reported more ill health on condition-speci

223 100% of Israeli patients with posttraumatic fibromyalgia returned to work.

224 Participants (n = 619) with fibromyalgia, rheumatoid arthritis, or osteoarthritis re

225 , prescribing factors, comorbidities such as fibromyalgia, rheumatological conditions, recent major s

226 , neuropathic pain (-6.8, -8.7 to -4.8), and fibromyalgia (risk ratio 1.4, 95% confidence interval 1.

227 ghtly at risk of postwar hospitalization for fibromyalgia (RR = 1.23, 95% Cl: 1.05, 1.43); however, t

228 Patients with fibromyalgia scored lower than the US norm on all SF-36

229 Patients with established fibromyalgia, seen in rheumatology centers in which ther

230 icantly associated with higher scores on the Fibromyalgia Severity Scale, consisting of Widespread Pa

231 efficacy of acupuncture in the treatment of fibromyalgia showed conflicting results, but added to th

232 ry gating deficits in the pathophysiology of fibromyalgia-spectrum manifestations.

233 t of the postulated autoimmunity showed that fibromyalgia subjects (FMS) had elevated levels of antib

234 ers, including functional motor disorder and fibromyalgia, suggesting a shared deficit in sensory inf

235 elf-report measures to assess pain severity, fibromyalgia survey criteria score, pain catastrophizing

236 ve as an objective transdiagnostic marker of fibromyalgia symptomatology or fibromyalgianess, includi

237 Duloxetine treatment improved fibromyalgia symptoms and pain severity regardless of ba

238 ionnaires which included questions regarding fibromyalgia symptoms and severity, utilization of servi

239 bromyalgia patients, studies have shown that fibromyalgia symptoms are not explained by depression al

240 All patients had persistence of some fibromyalgia symptoms, although almost half (48%) had no

241 tine, and milnacipran (on-label) in reducing fibromyalgia symptoms.

242 n findings have previously been described in fibromyalgia syndrome (FMS) by single-photon-emission co

243 Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal

244 Fibromyalgia Syndrome (FMS) is a chronic pain condition

245 Fibromyalgia Syndrome (FMS) is a frequent comorbidity in

246 Fibromyalgia syndrome (FMS) is characterized by uncertai

247 Fibromyalgia syndrome (FMS) is characterized by widespre

248 The optimal management of fibromyalgia syndrome (FMS) is unclear and comprehensive

249 ditures differ between insured patients with fibromyalgia syndrome (FMS) who visit complementary and

250 g and poor medical outcomes in patients with fibromyalgia syndrome (FMS), neither assessed these find

251 line and 1-year followup among patients with fibromyalgia syndrome (FMS).

252 iate, pain onset and health care seeking for fibromyalgia syndrome (FMS).

253 those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome (FMS).

254 onships of adolescents with juvenile primary fibromyalgia syndrome (JPFS) compared with matched class

255 ability of adolescents with juvenile primary fibromyalgia syndrome (JPFS) to cope with their conditio

256 A model of fibromyalgia syndrome produced by chronic unpredictable

257 g postoperative pain, noncardiac chest pain, fibromyalgia syndrome, and chronic back pain.

258 ypothesis that tender points, as part of the fibromyalgia syndrome, are strongly associated with spec

259 idespread pain, the clinical hallmark of the fibromyalgia syndrome, is associated with other physical

260 Both groups of patients with fibromyalgia taking and not taking opioids had similar l

261 controls (CON, n = 30), and individuals with fibromyalgia taking opioids (FMO, n = 27) and not taking

262 incentive delay (MID) task in patients with fibromyalgia taking opioids (N = 17), patients with fibr

263 pared to healthy controls, but patients with fibromyalgia taking opioids did not.

264 nkylosing spondylitis, rheumatoid arthritis, fibromyalgia) than those with NWU or LWU.

265 merous treatments are available for managing fibromyalgia that are supported by high-quality evidence

266 s for the treatment of pain in patients with fibromyalgia that may be also useful in patients with ot

267 Primary outcome measures included fibromyalgia, the chronic fatigue syndrome, dermatologic

268 ent is associated with an increased risk for fibromyalgia, the chronic fatigue syndrome, skin conditi

269 examined were the chronic fatigue syndrome, fibromyalgia, the irritable bowel syndrome, multiple che

270 igins of cerebral gray matter alterations in fibromyalgia, this study advances the understanding of t

271 (n = 252, 126 controls and 126 patients with fibromyalgia) through the analysis of their blood plasma

272 l evidence of a beneficial effect of tDCS in fibromyalgia, thus encouraging further trials.

273 We found decreased gray matter in fibromyalgia to be associated with T1 relaxation times,

274 th professionals to counsel individuals with fibromyalgia to become and remain more physically active

275 asic exercise principles to individuals with fibromyalgia to encourage clinicians to discuss with the

276 n a recently developed putative rat model of fibromyalgia to innocuous and acute nociceptive stimuli

277 report of genome-wide suggestive linkage of fibromyalgia to the chromosome 17p11.2-q11.2 region.

278 sibling recurrence risk ratio (lambdas ) for fibromyalgia was 13.6 (95% confidence interval 10.0-18.5

279 lvic pain or prostatitis was 11% (8-17); and fibromyalgia was 4% (3-7).

280 Fibromyalgia was diagnosed in 46.8% of CLD patients.

281 The medical literature on fibromyalgia was reviewed from 1955 to March 2014 via ME

282 ble bowel syndrome, chronic pelvic pain, and fibromyalgia were assessed by questionnaires.

283 Patients with fibromyalgia were divided into tertiles by change in pai

284 College of Rheumatology criteria for primary fibromyalgia were enrolled (89% female, 87% white, mean

285 Other symptoms of fibromyalgia were evaluated using the Fibromyalgia Impac

286 s with other rheumatic disorders, those with fibromyalgia were more likely to have lifetime surgical

287 led trials of cyclobenzaprine in people with fibromyalgia were obtained from Medline, EMBase, Psyclit

288 oup, escalating-dose trial, 60 patients with fibromyalgia were randomized 2:1 (pramipexole:placebo) t

289 Forty females with fibromyalgia were randomized to receive active or sham t

290 merican College of Rheumatology criteria for fibromyalgia were randomized to receive esreboxetine at

291 Patients diagnosed with fibromyalgia were recruited from a Southern California h

292 investigated therapies for individuals with fibromyalgia were screened for inclusion.

293 Preoperative IBS and fibromyalgia were strong predictors of postoperative IBS

294 steoarthritis (OA), rheumatoid arthritis, or fibromyalgia who were participating in a long-term outco

295 was performed to assess 1,025 patients with fibromyalgia who were randomized to receive milnacipran

296 tion on depressive symptoms in 91 women with fibromyalgia who were randomly assigned to treatment (n

297 ging to compare 26 postmenopausal women with fibromyalgia with 25 healthy controls (age range: 50-75

298 a model-free genome-wide linkage analysis of fibromyalgia with 341 microsatellite markers, using the

299 mmonly reported but anecdotal association of fibromyalgia with whiplash-type neck trauma was validate

300 tentional processing of reward is altered in fibromyalgia within LOC-IFG brain circuits, possibly to